David Elsley

David Elsley is the Chief Executive Officer of Cardiol Therapeutics Inc. (TSX: CRDL, NASDAQ: CRDL), a clinical-stage biotechnology company developing innovative cannabidiol-based therapies for heart disease. With over three decades of experience in biotechnology, Elsley founded Vasogen Inc. in 1990, a company focused on developing novel therapeutics for heart failure and inflammatory conditions.

At Cardiol Therapeutics, Elsley leads the development of CardiolRx™, a pharmaceutical-grade cannabidiol formulation targeting acute myocarditis and recurrent pericarditis. The company has received FDA Investigational New Drug Application authorization for Phase II clinical trials, including the multinational ARCHER trial for acute myocarditis, a leading cause of sudden cardiac death in people under 35. Under his leadership, Cardiol has also secured FDA Orphan Drug Designation for their myocarditis program.

While Elsley's expertise lies primarily in biotechnology and pharmaceutical development rather than natural resources, his company's focus on cannabidiol-based therapeutics represents an intersection with the agricultural commodity sector. However, his relevance to traditional commodity and mining investors is limited, as his work centers on clinical-stage drug development rather than resource extraction or commodity trading.